Sartorius Stedim Biotech Acquires Majority Stake in AllPure Technologies
Sartorius Stedim Biotech's acquisition of AllPure Technologies will extends its portfolio for single-use bioprocessing.
Sartorius Stedim Biotech has signed a contract to acquire the majority stake in the US start-up, AllPure Technologies LLC. The privately owned company based in New Oxford, PA, has been in operation for four years, and earned revenue of approximately $3 million in 2013 with 25 employees. AllPure specializes in single-use components for biopharmaceutical applications, such as aseptic sampling techniques. The parties agreed not to disclose any further details of the purchase agreement.
Source: Sartorius Stedim Biotech
Texas' MD Anderson Cancer Center Creates New Cell Therapy Institute
November 11th 2024With the launch of the Institute for Cell Therapy Discovery and Innovation, the MD Anderson Cancer Center will bring together expertise in developing cell therapies for cancer, autoimmune diseases, and infections.
